SynthesisNeurotoxicity research2022
Nanotechnology in Improving the Treatment of Huntington's Disease: a Systematic Review.
Synthesis in Neurotoxicity research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Surface-Engineered Precision Nano-Systems for Targeted Treatment of Huntington's Disease: A Review of Recent Advancements.International journal of nanomedicine · 2026Review
- Nanoneuroscience: Cutting-edge Approach for Disease Management.Recent patents on nanotechnology · 2024Review
- Nanotechnology-empowered therapeutics targeting neurodegenerative diseases.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Huntington's disease (HD) is a degenerative genetic condition characterized by cognitive, motor, and psychiatric disturbance. It is caused by a dominantly inherited alteration in the huntingtin gene. Even though symptomatic management is the mainstay of HD treatment, in the thesis, one of the leading causes of the low success of current therapy is their low efficacy for crossing the blood-brain barrier (BBB). The improvement in drug delivery through the BBB may be achieved by some endogenous uptake mechanisms and nanocarrier systems, increasing the bioavailability and slow-release of macromolecular drugs in the central nervous system. In the present study, we present state-of-the-art scientific production on nanotechnology in the treatment of HD symptoms. Here, we discussed the benefits of nanotechnology pharmacological therapy tested in rodent animal models and in vitro specific analyses. We presented why we could apply nanotechnology to improve the transport of drugs through BBB based on already postulated hypotheses about potential pharmacological therapy against some HD symptoms.
Indexed as
Identifiers
35060083What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.